Abbott Laboratories Stock Hits Day Low of $105.40 Amid Price Pressure

Abbott Laboratories experienced a significant decline today, with the stock dropping by 4.74% as it reached an intraday low of USD 105.40. This performance stands in contrast to the S&P 500, which fell by 1.51% during the same period. Over the past week, Abbott's stock has decreased by 4.34%, while its monthly performance shows a decline of 6.91%. In the longer term, Abbott Laboratories has faced challenges, with a 16.5% drop over the past year, compared to a 14.9% increase in the S&P 500. Year-to-date, the stock is down 15.83%, while the S&P 500 has declined by 4.95%. However, the company maintains a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 0.62 times. Abbott has reported positive operating cash flow, reaching its highest at USD 9,037 million, and has shown healthy long-term growth with an annual operating profit increase of 13.45%. Despite today's downturn, the company continues to demonstrate solid financial metrics within the pharmaceuticals and biotechnology sector.